Cargando…

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC. Thirty patients with pathologically confirmed advanced ICC received in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Guo-Ming, Huang, Xiao-Yong, Wu, Dong, Sun, Hui-Chuan, Liang, Fei, Ji, Yuan, Chen, Yi, Yang, Guo-Huan, Lu, Jia-Cheng, Meng, Xian-Long, Wang, Xin-Ying, Sun, Lei, Ge, Ning-Ling, Huang, Xiao-Wu, Qiu, Shuang-Jian, Yang, Xin-Rong, Gao, Qiang, He, Yi-Feng, Xu, Yang, Sun, Jian, Ren, Zheng-Gang, Fan, Jia, Zhou, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020443/ https://www.ncbi.nlm.nih.gov/pubmed/36928584 http://dx.doi.org/10.1038/s41392-023-01317-7

Ejemplares similares

Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma
por: Zhang, Chi, et al.
Publicado: (2013)

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion
por: Meng, Xian-Long, et al.
Publicado: (2022)

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
por: Zhu, Chengpei, et al.
Publicado: (2023)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
por: Gao, Yang, et al.
Publicado: (2021)

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
por: Sun, Bao-Ye, et al.
Publicado: (2022)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma
por: Song, Fei, et al.
Publicado: (2021)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma
por: Song, Guohe, et al.
Publicado: (2022)

EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma
por: Hao, Xiao-Yi, et al.
Publicado: (2016)

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways
por: Chen, Xu-Xiao, et al.
Publicado: (2018)

Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Yi, Xiao, et al.
Publicado: (2023)

Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients
por: Huang, Xiao-Yong, et al.
Publicado: (2014)

Biomarkers for predicting the prognosis of intrahepatic cholangiocarcinoma: A retrospective single-center study
por: Li, Xueliang, et al.
Publicado: (2023)

Evaluating prognostic value of biliary stone in intrahepatic cholangiocarcinoma by propensity score matching analysis
por: Wang, Yupeng, et al.
Publicado: (2023)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Publisher Correction: Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma
por: Song, Guohe, et al.
Publicado: (2022)

Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
por: Zhang, Jun-Wei, et al.
Publicado: (2023)

Clinicopathological features of 11 Epstein–Barr virus-associated intrahepatic cholangiocarcinoma at a single center in China
por: Sun, Ke, et al.
Publicado: (2016)

A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma
por: Zheng, Bo-Hao, et al.
Publicado: (2017)

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
por: Sun, Bao-Ye, et al.
Publicado: (2023)

Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
por: Song, Fei, et al.
Publicado: (2020)

Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma
por: Xie, Nan, et al.
Publicado: (2017)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection
por: Jing, Chu-Yu, et al.
Publicado: (2016)

Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma
por: Zhou, Shao-Lai, et al.
Publicado: (2021)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
por: Huang, Kai-Kai, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria
por: Guo, De-Zhen, et al.
Publicado: (2022)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
por: Lu, Jia-Cheng, et al.
Publicado: (2019)

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target
por: Gao, Qiang, et al.
Publicado: (2014)

Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
por: Zhou, Zhengjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nv2m12bs7e4il7rigji697v9vn